Conatus Late-breaker Oral Presentation at EASL Meeting Details Results of ENCORE-PH Phase 2b Clinical Trial in Patients with ...
April 15 2019 - 7:30AM
Conatus Pharmaceuticals Inc. (NASDAQ: CNAT) announced today that
the company’s late-breaker oral presentation at The International
Liver Congress™ 2019, the Annual Meeting of the European
Association for the Study of the Liver (EASL) in Vienna, Austria,
April 10-14, was also selected by EASL for inclusion in the “Best
of ILC” summary slide deck highlighting the most noteworthy
contributions to the scientific program at this year’s meeting.
The oral presentation at EASL entitled, “Multicenter,
Double-blind, Placebo-controlled, Randomized Trial of Emricasan in
Subjects with NASH Cirrhosis and Severe Portal Hypertension (PH),”
(#LB01) detailed results from the company’s Phase 2b ENCORE-PH
clinical trial of emricasan, the company’s first-in-class, orally
active pan-caspase protease inhibitor. Guadalupe Garcia-Tsao, M.D.,
Professor of Medicine in the Section of Digestive Diseases at Yale
School of Medicine, Director of the Clinical and Translational Core
at Yale Liver Center, Chief of the Section of Digestive Diseases at
the Veterans Administration-Connecticut Health Care System, and the
central reader in the ENCORE-PH trial, delivered the presentation
on Saturday, April 13, at 4:00 p.m. CEST. A copy of the
presentation is available in the Investors section of the Conatus
website at www.conatuspharma.com.
About Conatus PharmaceuticalsConatus is a
biotechnology company focused on the development and
commercialization of novel medicines to treat chronic diseases with
significant unmet need. In collaboration with Novartis, Conatus is
developing its lead in-licensed compound, emricasan, for the
treatment of patients with NASH-driven chronic liver diseases.
Conatus is independently developing its lead internally developed
compound, CTS-2090, for the treatment of patients with chronic
diseases involving inflammasome pathways. For additional
information, please visit www.conatuspharma.com.
Forward-Looking StatementsThis press release
contains forward-looking statements within the meaning of Section
21E of the Securities Exchange Act of 1934, as amended. All
statements other than statements of historical facts contained in
this press release are forward looking statements. In some
cases, you can identify forward-looking statements by terms such as
“may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,”
“intend,” “target,” “project,” “contemplates,” “believes,”
“estimates,” “predicts,” “potential” or “continue” or the negative
of these terms or other similar expressions. These
forward-looking statements speak only as of the date of this press
release and are subject to a number of risks, uncertainties and
assumptions, including those risks described in the company’s prior
press releases and in the periodic reports it files with the
Securities and Exchange Commission. The events and
circumstances reflected in the company’s forward-looking statements
may not be achieved or occur and actual results could differ
materially from those projected in the forward-looking statements.
Except as required by applicable law, the company does not plan to
publicly update or revise any forward-looking statements contained
herein, whether as a result of any new information, future events,
changed circumstances or otherwise.
CONTACT: Alan EngbringConatus
Pharmaceuticals Inc.(858) 376-2637aengbring@conatuspharma.com
Conatus Pharmaceuticals (NASDAQ:CNAT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Conatus Pharmaceuticals (NASDAQ:CNAT)
Historical Stock Chart
From Apr 2023 to Apr 2024